Aicar Benefits: What Studies Report

AICAR (5-aminoimidazole-4-carboxamide ribonucleotide, also written acadesine) is a purine nucleoside intermediate that cells convert to a monophosphate form that mimics AMP, which is why it has been used in laboratories as a pharmacological activator of AMP-activated protein kinase (AMPK). Because AMPK sits at the centre of energy-sensing pathways that exercise also engages, AICAR appears repeatedly in the "exercise in a pill" literature. A 2017 review in Brain Plasticity surveyed exercise mimetics and discussed the molecular pathways these candidate compounds target alongside the effects of physical activity itself (PMID 29765854).

This page organises what published studies have actually measured, by outcome domain. It does not state that AICAR produces any benefit in people. Where the available evidence is animal, zebrafish, cell-culture or review-level, that is labelled; where a commonly searched benefit has little or no supporting evidence in this citation set, that is said plainly. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision or medical condition.

How the evidence in this citation set breaks down

Nothing below comes from a human efficacy trial of AICAR. The strongest-sounding claims in popular summaries trace back to mechanistic work in mice, zebrafish and cultured cells, or to narrative reviews of AMPK and mitochondrial biology such as a 2018 review on modulating mitophagy in mitochondrial disease (PMID 28618992) and a 2024 review on targeting AMPK in sepsis (PMID 39469575). Readers comparing sources should track three things for every claim: the species, the measured endpoint, and whether AICAR itself or a related pathway was the subject.

Endurance and "exercise in a pill": what studies report

The idea that AICAR can substitute for training is the most searched claim attached to the compound. In the verified literature here, that idea is discussed at review level rather than demonstrated in human performance trials: the 2017 exercise-mimetics review examined compounds proposed to reproduce molecular features of exercise and placed them beside the documented effects of exercise on the brain (PMID 29765854). A review is a synthesis, not an outcome trial, and it cannot establish that a compound improves endurance in healthy people.

For contrast, when researchers tested actual training protocols against a metabolic complication, a 2024 study in Diabetes reported that high-intensity interval training, caloric restriction, or their combination had beneficial effects on metabolically acquired peripheral neuropathy (PMID 39163551). That is lifestyle-intervention evidence, not evidence about AICAR, and it illustrates the gap between studying exercise and studying a compound said to imitate it.

What this does not show

• No study in this citation set reported VO₂ max, time-trial performance or training adaptation outcomes in humans given AICAR.
• No dose, schedule or duration for human use appears in these abstracts, so none is stated on this page.
• The reviewed exercise-mimetic concept was framed as a research direction in brain plasticity rather than a performance result (PMID 29765854).

Skeletal muscle and mitochondrial signalling

AICAR's biochemistry links it to the ATIC enzyme, the bifunctional protein that acts on AICAR ribonucleotide during purine synthesis. A 2025 study in Free Radical Biology & Medicine reported that aerobic exercise ameliorated skeletal muscle atrophy in atic knockout zebrafish through the oxidative phosphorylation pathway (PMID 40623538). The direction of effect there was favourable for exercise in a genetic model that disrupts this purine pathway; the study was conducted in zebrafish, and it did not test AICAR supplementation in people.

Mitochondrial claims are frequently attached to AMPK activators generally. A 2018 review in Current Medicinal Chemistry discussed strategies for modulating mitophagy — the selective clearance of damaged mitochondria — in mitochondrial disease (PMID 28618992). Reviews of this kind describe candidate mechanisms and research tools; they do not report that any one compound improved patient-level outcomes. Separately, researchers reported in a 2024 Gut Microbes paper that high-fat-diet-induced L-saccharopine accumulation inhibited estradiol synthesis and damaged oocyte quality by disturbing mitochondrial homeostasis in a model system (PMID 39410876) — relevant to how diet and mitochondrial handling intersect, but not an AICAR benefit finding.

Brain, memory and ischemia models

Claims about cognition usually borrow from exercise biology. In a 2016 Cell Metabolism paper, researchers reported that running-induced systemic secretion of cathepsin B was associated with memory function (PMID 27345423). The exposure studied there was running; any extension of that association to a compound is an inference, not a reported result.

Within the AMPK pathway itself, a 2025 study in Metabolism reported a neuroprotective effect of small extracellular vesicle-mediated targeting of AMPKα2 in cerebral ischemia (PMID 39961478). That work used a targeted delivery strategy in a preclinical ischemia model rather than systemic AICAR administration, and the endpoint was neuroprotection in that model, not cognitive enhancement in healthy subjects.

Immune function, infection and inflammation

AMPK and purine metabolism both intersect with host defence, which is why AICAR appears in immunology methods sections as a pathway tool. A 2024 review in Frontiers in Endocrinology examined targeting AMP-activated protein kinase in sepsis and set out why the pathway has attracted interest in critical-illness research (PMID 39469575). A 2025 paper in Signal Transduction and Targeted Therapy reported that purine nucleoside phosphorylase dominated influenza A virus replication and host hyperinflammation through purine salvage (PMID 40517177), placing purine-pathway handling squarely inside antiviral and inflammatory biology.

Antiviral claims are sometimes transferred between metabolic drugs. Researchers reported in a 2023 Virus Research paper that metformin suppressed SARS-CoV-2 in cell culture (PMID 36417940). That finding concerned metformin, in vitro, and does not establish anything about AICAR in people; it is included here because the two compounds are often grouped together as metabolic pathway modulators.

Cancer and immune surveillance

Searches for AICAR sometimes carry oncology expectations. The relevant work in this citation set is mechanistic: a 2025 Nature Communications study reported that CD137L promoted immune surveillance in melanoma via HLTF regulation (PMID 41006211). The direction of effect there favoured enhanced immune surveillance in the models studied, and the subject of the paper was the CD137L–HLTF axis. No human clinical outcome for AICAR in cancer appears in the verified papers assembled for this page.

Organ preservation and transplant research

A 2026 paper in the American Journal of Respiratory Cell and Molecular Biology reported that ex vivo lung perfusion enhanced donor lung preservation in mice via Hippo signaling activation (PMID 40996835). Metabolic-stress signalling is central to preservation research, which is why AICAR-adjacent pathway work surfaces in this field. The measured outcome in that study was donor lung preservation in mice, not a benefit in a living recipient of any compound.

Adverse Events and Safety Signals: What Studies Report

The verified papers summarised on this page are mechanistic studies, animal models and reviews; none of them is a human safety trial of AICAR, and none reports a tolerability profile, adverse-event rate or long-term follow-up for people using the compound. The closest safety-adjacent discussion is pathway-level: the 2024 AMPK-in-sepsis review framed AMPK activation as a target under investigation in a critically ill population rather than an established therapy (PMID 39469575), and the 2018 mitophagy review discussed modulation of mitochondrial quality control as a research strategy in mitochondrial disease (PMID 28618992).

Two general cautions follow from that. First, absence of reported adverse events in mechanistic literature is not evidence of safety — those studies were not designed to detect harm in humans. Second, pathways that look beneficial in one model can be context-dependent: purine salvage, for example, was reported to drive both viral replication and host hyperinflammation in influenza A research (PMID 40517177), a reminder that modulating a metabolic node is not uniformly favourable.

Where the evidence is weak or absent

• Fat loss and body composition in humans: no study in this citation set measured weight, fat mass or body composition outcomes after AICAR administration in people.
• Athletic performance: the exercise-mimetic concept was discussed at review level (PMID 29765854), while actual performance and metabolic benefit data in these papers came from exercise interventions such as high-intensity interval training (PMID 39163551).
• Cognition and memory: the memory association reported was with running-induced cathepsin B secretion, not with a compound (PMID 27345423).
• Longevity: no lifespan or healthspan endpoint appears in the verified papers used here.
• Dosing: no human dose, frequency or duration is supported by these abstracts, so none is described.

Regulatory and research context

AICAR is not an approved therapeutic product for performance, metabolic or cognitive indications, and material sold in research channels is typically labelled for research use only. It also appears on anti-doping prohibited lists as a metabolic modulator, which is a regulatory fact rather than a statement about efficacy or safety. Nothing here is legal advice. Readers tracking the science can note that the research framing in these papers is consistently mechanistic — pathway targeting in sepsis (PMID 39469575) and mitophagy modulation in mitochondrial disease (PMID 28618992) — rather than consumer-outcome framing.

Related reading

For background on what AICAR is, how it is classified, and how the AMPK pathway is described in the literature, see the AICAR overview.

References

• Exercise in a Pill: The Latest on Exercise-Mimetics (Brain Plasticity, 2017)
• Running-Induced Systemic Cathepsin B Secretion Is Associated with Memory Function (Cell Metabolism, 2016)
• Modulating Mitophagy in Mitochondrial Disease (Current Medicinal Chemistry, 2018)
• Aerobic exercise ameliorates skeletal muscle atrophy in atic knockout zebrafish through the oxidative phosphorylation pathway (Free Radical Biology & Medicine, 2025)
• Neuroprotective effect of small extracellular vesicle-mediated targeting of AMPKα2 in cerebral ischemia (Metabolism, 2025)
• Targeting AMP-activated protein kinase in sepsis (Frontiers in Endocrinology, 2024)
• Purine nucleoside phosphorylase dominates Influenza A virus replication and host hyperinflammation through purine salvage (Signal Transduction and Targeted Therapy, 2025)
• Metformin suppresses SARS-CoV-2 in cell culture (Virus Research, 2023)
• CD137L promotes immune surveillance in melanoma via HLTF regulation (Nature Communications, 2025)
• High-fat diet-induced L-saccharopine accumulation inhibits estradiol synthesis and damages oocyte quality by disturbing mitochondrial homeostasis (Gut Microbes, 2024)
• Ex vivo lung perfusion enhances donor lung preservation in mice via Hippo signaling activation (American Journal of Respiratory Cell and Molecular Biology, 2026)
• High-Intensity Interval Training, Caloric Restriction, or Their Combination Have Beneficial Effects on Metabolically Acquired Peripheral Neuropathy (Diabetes, 2024)